C. Wee, Jin Ho Kim, H. Kim, Hyun-Cheol Kang, S. Suh, B. Shin, E. Ma, I. Kim
{"title":"Psammaplin a修饰的新型放射增敏剂用于人肺癌和胶质母细胞瘤细胞","authors":"C. Wee, Jin Ho Kim, H. Kim, Hyun-Cheol Kang, S. Suh, B. Shin, E. Ma, I. Kim","doi":"10.14407/JRPR.2019.44.1.15","DOIUrl":null,"url":null,"abstract":"1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea; 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; 3Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; 4School of Pharmacy, Sungkyunkwan University, Suwon, Korea; 5College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells\",\"authors\":\"C. Wee, Jin Ho Kim, H. Kim, Hyun-Cheol Kang, S. Suh, B. Shin, E. Ma, I. Kim\",\"doi\":\"10.14407/JRPR.2019.44.1.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea; 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; 3Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; 4School of Pharmacy, Sungkyunkwan University, Suwon, Korea; 5College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2019-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14407/JRPR.2019.44.1.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14407/JRPR.2019.44.1.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea; 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; 3Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; 4School of Pharmacy, Sungkyunkwan University, Suwon, Korea; 5College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
